Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RL-007 Safety and EEG/ERP Study in Schizophrenia
NCT04822883Phase 2Completed
- Sponsor
- Recognify Life Sciences
- Start
- Apr 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of inidascamine in schizophrenia, sponsored by Recognify Life Sciences. Started Apr 2021; status: completed.
02
Drugs
inidascamine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04822883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04822883.